Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)

NCT04795869 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT04795869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04795869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Withdrawn
Start date
March 1, 2020
Completion date
March 31, 2029
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent angioimmunoblastic t-cell lymphoma, recurrent enteropathy-associated t-cell lymphoma, recurrent follicular t-cell lymphoma, recurrent hepatosplenic t-cell lymphoma, recurrent nodal peripheral t-cell lymphoma with tfh phenotype, recurrent peripheral t-cell lymphoma, not otherwise specified, recurrent subcutaneous panniculitis-like t-cell lymphoma, refractory angioimmunoblastic t-cell lymphoma, refractory enteropathy-associated t-cell lymphoma, refractory follicular t-cell lymphoma, refractory hepatosplenic t-cell lymphoma, refractory nodal peripheral t-cell lymphoma with tfh phenotype, refractory peripheral t-cell lymphoma, not otherwise specified, refractory subcutaneous panniculitis-like t-cell lymphoma